Dow Up0.51% Nasdaq Up0.24%

Orexigen Therapeutics, Inc. (OREX)

5.88 Up 0.12(2.08%) Nov 21, 4:00PM EST
|After Hours : 5.84 Down 0.04 (0.68%) Nov 21, 7:50PM EST
ProfileGet Profile for:
Orexigen Therapeutics, Inc.
3344 North Torrey Pines Court
Suite 200
La Jolla, CA 92037
United States - Map
Phone: 858-875-8600
Fax: 858-875-8650

Index Membership:N/A
Industry:Drug Manufacturers - Other
Full Time Employees:50

Business Summary 

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials. Orexigen Therapeutics, Inc. has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The company was founded in 2002 and is headquartered in La Jolla, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Orexigen Therapeutics, Inc.

Corporate Governance 
Orexigen Therapeutics, Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 10. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 8; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Michael A. Narachi M.S., M.B.A., 55
Chief Exec. Officer, Pres and Director
Mr. Joseph P. Hagan , 45
Acting Chief Financial Officer, Principal Accounting Officer, Chief Bus. Officer and Treasurer
Ms. Heather D. Turner J.D., 41
Sr. VP, Gen. Counsel and Sec.
Mr. Mark D. Booth , 54
Chief Commercial Officer
Dr. Preston S. Klassen M.D., M.H.S., 45
Head of Global Contrave Program and Sr. VP of Product Devel.
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders